Status | Study |
Recruiting |
Study Name: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Condition: Cervical Adenosarcoma Cervical Adenosquamous Carcinoma Cer Date: 2013-12-19 Interventions: Biological: Bevacizumab Given |
Withdrawn |
Study Name: Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) Condition: Endometrioid Carcinoma Clear Cell Carcinoma Date: 2012-11-18 |
Recruiting |
Study Name: Improving the Treatment for Women With Early Stage Cancer of the Uterus Condition: Complex Endometrial Hyperplasia With Atypia Grade 1 Endometrial Endome Date: 2012-09-12 Interventions: Drug: Levonorgestrel Intrauter |
Active, not recruiting |
Study Name: Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Condition: Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Mucin Date: 2010-07-21 Interventions: Biological: Bevacizumab Given |
Active, not recruiting |
Study Name: Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid A Date: 2010-02-23 Interventions: Drug: Bortezomib Given IP |
Active, not recruiting |
Study Name: Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Carcinosarcoma Fallopian Tube Clear Cell Adenocarcinoma Date: 2009-10-02 Interventions: Biological: Bevacizumab Given |
Active, not recruiting |
Study Name: Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid A Date: 2009-04-24 Interventions: Drug: Elesclomol Sodium Given |
Recruiting |
Study Name: Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid A Date: 2008-07-18 Interventions: Behavioral: Behavioral Dietary Intervention |
Recruiting |
Study Name: Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Condition: Clear Cell Adenocarcinoma Fallopian Tube Clear Cell Adenocarcinoma Date: 2007-11-29 Interventions: Biological: Bevacizumab Given |
Completed |
Study Name: Mifepristone for Patients With Endometrial Cancer and LGESS Condition: Endometrial Cancer Date: 2007-07-19 Interventions: Drug: Mifepristone 200 mg by mouth (PO) Daily x 4 Weeks |